The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
 
Florent Peyraud
No Relationships to Disclose
 
Jean-Philippe Guegan
No Relationships to Disclose
 
Christophe Rey
No Relationships to Disclose
 
Sophie Cousin
No Relationships to Disclose
 
Guilhem Roubaud
No Relationships to Disclose
 
Mathilde Cabart
Employment - STERIS (I)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen Oncology; Pfizer; Sanofi
 
Maxime Brunet
No Relationships to Disclose
 
Ezogelin Oflazoglu Gruyters
Employment - AstraZeneca/MedImmune
 
Ariel Savina
Employment - AstraZeneca/MedImmune
 
Sylvestre Le Moulec
No Relationships to Disclose
 
Bérangère Dadone-Montaudon
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Centessa Pharmaceuticals (Inst); Deka Biosciences; HiFiBiO Therapeutics; HotSpot Therapeutics; PEGASCY (Inst); Shattuck Labs
Consulting or Advisory Role - AstraZeneca; BiolineRx; Centessa Pharmaceuticals; Clover Biopharmaceuticals; Deka Biosciences; Depth Charge Therapeutics; Eisai; Gritstone Bio; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MedinCell; MSD; OSE Immunotherapeutics; Pierre Fabre; Redx Pharma; Roche; SERVIER; Shattuck Labs; Sotio; Third Rock Ventures
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - Sotio
 
Jean-Charles Soria
Employment - Amgen; AstraZeneca/MedImmune
Leadership - Hookipa Pharma
Stock and Other Ownership Interests - AstraZeneca; Daiichi Sankyo (I); Gritstone Bio; Relay Therapeutics
Honoraria - Relay Therapeutics
 
Jean-Yves Scoazec
No Relationships to Disclose
 
François Le Loarer
No Relationships to Disclose
 
Alban Bessede
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS